Glenmark Pharmaceuticals Ltd. (BSE:532296) reportedly intends to pursue acquisitions. Glenmark is reportedly looking at an acquisition of a specialty-brand marketing firm in the US for brand development.

Glenmark Pharmaceuticals Ltd. announced that at the meeting of the board of directors of the company held on May 07, 2013, Mr. Marshall Mendonza Vice President & Company Secretary ceased to be the Company Secretary of the company consequent to his retirement. At the same meeting, Mr. Sanjay Kumar Chowdhary was appointed as the Company Secretary & Compliance Officer of the company.

Glenmark Pharmaceuticals Ltd. reported audited standalone and consolidated earnings results for the fourth quarter and full year ended March 31, 2013. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 4,841.36 million against INR 4,502.02 million for the same period in the last year. Profit from operations before other income, finance costs and exceptional items was INR 517.14 million against INR 1,399.12 million for the same period in the last year. Profit from ordinary activities before tax was INR 719.62 million against INR 1,411.46 million for the same period in the last year. Net profit was INR 849.19 million against INR 1,482.32 million for the same period in the last year. Earnings per diluted share before and after extraordinary items (not annualized) were INR 3.13 against INR 5.48 for the same period in the last year. For the year, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 19,352.88 million against INR 15,468.16 million for the same period in the last year. Profit from operations before other income, finance costs and exceptional items was INR 3,074.03 million against INR 2,898.62 million for the same period in the last year. Profit from ordinary activities before tax was INR 3,799.54 million against INR 2,840.97 million for the same period in the last year. Net profit was INR 3,861.07 million against INR 2,652.99 million for the same period in the last year. Earnings per diluted share before and after extraordinary items (not annualized) were INR 14.25 against INR 9.80 for the same period in the last year. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 13,354.85 million against INR 10,658.56 million for the same period in the last year. Profit from operations before other income, finance costs and exceptional items was INR 2,229.49 million against INR 1,981.23 million for the same period in the last year. Profit from ordinary activities before tax was INR 1,744.00 million against INR 1,594.90 million for the same period in the last year. Net profit was INR 1,698.35 million against INR 1,522.26 million for the same period in the last year. Earnings per diluted share before and after extraordinary items (not annualized) were INR 6.15 against INR 5.55 for the same period in the last year. For the year, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 50,123.42 million against INR 40,206.13 million for the same period in the last year. Profit from operations before other income, finance costs and exceptional items was INR 8,843.59 million against INR 7,492.00 million for the same period in the last year. Profit from ordinary activities before tax was INR 7,337.15 million against INR 4,880.91 million for the same period in the last year. Net profit was INR 6,230.00 million against INR 4,643.07 million for the same period in the last year. Earnings per diluted share before and after extraordinary items (not annualized) were INR 22.69 against INR 17.01 for the same period in the last year.